180 related articles for article (PubMed ID: 32926446)
1. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
Mali G; Ahuja V; Dubey K
J Clin Pharm Ther; 2021 Feb; 46(1):99-105. PubMed ID: 32926446
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
3. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
[TBL] [Abstract][Full Text] [Related]
4. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
5. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database.
García MG; Larrinaga-Torrontegui U; Eduardo Martinez E; Lertxundi U; Palacios-Zabalza I; Aguirre C
Am J Ther; 2019; 26(5):e589-e592. PubMed ID: 29324463
[TBL] [Abstract][Full Text] [Related]
6. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
7. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
Tobaiqy M; Elkout H
Int J Clin Pharm; 2024 Apr; 46(2):488-495. PubMed ID: 38265519
[TBL] [Abstract][Full Text] [Related]
10. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
García M; Arteche-Martinez U; Lertxundi U; Aguirre C
J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
13. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM
Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Alves C; Batel-Marques F; Macedo AF
Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
[TBL] [Abstract][Full Text] [Related]
17. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
Aung MM; Slade K; Freeman LAR; Kos K; Whatmore JL; Shore AC; Gooding KM
Diabetologia; 2019 Sep; 62(9):1701-1711. PubMed ID: 31203378
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Ruggiero R; Mascolo A; Spezzaferri A; Carpentieri C; Torella D; Sportiello L; Rossi F; Paolisso G; Capuano A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399362
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
